Percheron Therapeutics Ltd Chief Executive Officer talked with Proactive about the company’s lead oncology program HMBD-002 and the progress made following the completion of Phase I clinical trials.
Dr Garner outlined how the company has repositioned itself around HMBD-002, an immuno-oncology drug designed to activate the body’s immune system to target cancer. Garner explained that the therapy represents a fresh start for the company after a challenging period, describing the asset as “a completely different drug” with “no scientific relationship” to previous programs.
For more interviews and biotech insights, visit Proactive’s YouTube channel, give this video a like, subscribe to the channel, and enable notifications so you never miss an update.
#PercheronTherapeutics #ASXPER #HMBD002 #CancerResearch #Immunotherapy #BiotechStocks #ClinicalTrials #Oncology #BiotechInvesting #SmallCapBiotech